The Brazil Leukapheresis Market was valued at $1.4 Million in 2026 and projected to reach to $1.94 Million by 2031, representing a compound annual growth rate of CAGR 6.7%. Brazil's leukapheresis market is positioned for steady growth driven by increasing adoption of advanced cell therapies and immunotherapies in major medical centers.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
Brazil's leukapheresis market is valued at USD 1.4 million in 2026, expanding to USD 1.94 million by 2031 at a CAGR of 6.7%, outpacing many Latin American peers in cell therapy adoption.
Rising investment in CAR-T cell therapies and immunotherapy treatments across Brazilian hospitals and research institutions is driving demand for advanced leukapheresis equipment and services.
Brazil's modernizing healthcare system, supported by government initiatives and private sector growth, is enhancing access to sophisticated cell collection and processing technologies.
As Latin America's largest economy, Brazil represents a strategic hub for leukapheresis technology adoption, influencing broader regional market trends and clinical practice standards.
| Report Metric | Details |
|---|---|
| Base Year | 2026 |
| Fastest Growing Segment | MULTIPLE MYELOMA (Indication) |
| Forecast Period | 2026–2031 |
| Growth Rate | CAGR of 8.9% from 2026 to 2031 |
| Largest Segment | ACUTE LYMPHOCYTIC LEUKEMIA (Indication) |
| Market Size Base Year (Billions) | ~USD 0.09 (2026) |
| Revenue Forecast (Billions) | ~USD 0.14 (2031) |
| Segments Covered | Product Type, Product Type 2024–2031, Type, Application, End User, Indication, Leukopak Type |
7 segment dimensions are covered across the global market.
| Segment | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | CAGR (%) |
|---|---|---|---|---|---|---|---|---|---|
| ACADEMIC & RESEARCH INSTITUTES | 0.22 | 0.23 | 0.25 | 0.26 | 0.28 | 0.3 | 0.32 | 0.34 | 6.3 |
| BLOOD COMPONENT PROVIDERS & BLOOD CENTERS | 0.86 | 0.92 | 0.99 | 1.06 | 1.15 | 1.24 | 1.33 | 1.44 | 7.7 |
| HOSPITALS & TRANSFUSION CENTERS | 0.3 | 0.32 | 0.35 | 0.37 | 0.4 | 0.43 | 0.46 | 0.49 | 7.1 |
| PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES | 0.14 | 0.14 | 0.15 | 0.16 | 0.16 | 0.17 | 0.18 | 0.19 | 5.1 |
| TOTAL | 1.52 | 1.62 | 1.74 | 1.85 | 1.99 | 2.13 | 2.29 | 2.45 | 7.2 |
| Segment | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | CAGR (%) |
|---|---|---|---|---|---|---|---|---|---|
| ACADEMIC & RESEARCH INSTITUTES | 6.79 | 7.43 | 8.15 | 8.97 | 9.88 | 10.9 | 12.06 | 13.38 | 10.4 |
| CONTRACT RESEARCH ORGANIZATIONS | 0.46 | 0.49 | 0.53 | 0.57 | 0.61 | 0.66 | 0.71 | 0.77 | 8 |
| PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES | 2.2 | 2.44 | 2.72 | 3.03 | 3.39 | 3.8 | 4.27 | 4.8 | 12 |
| TOTAL | 9.44 | 10.36 | 11.4 | 12.56 | 13.88 | 15.36 | 17.04 | 18.95 | 10.7 |
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| MAXCYTE, INC | United States | Public Company | ExPERT instruments (ATx, STx, GTx, VLx),Disposable processing assemblies (PAs) and consumables,Licensing and technology access fees, |
MaxCyte, Inc. is a United States-based biotechnology company founded in 1998 that specializes in cell engineering technologies. As a publicly traded company, MaxCyte operates with 91 employees and develops innovative solutions for cell-based therapies and research applications.
Brazil's leukapheresis market is estimated at USD 1.4 million in 2026.
Brazil's leukapheresis market is projected to reach USD 1.94 million by 2031.
Brazil's leukapheresis market is expected to grow at a compound annual growth rate (CAGR) of 6.7% from 2026 to 2031.
Growth in Brazil is driven by rising prevalence of hematologic malignancies, increasing adoption of CAR-T cell therapy, improving healthcare infrastructure, and regulatory alignment with international standards.
Brazil represents a key growth market within Latin America's leukapheresis landscape, with expanding institutional investment and clinical adoption of advanced cell therapy technologies.
This study extensively used both primary and secondary sources. The research involved studying various factors affecting the industry to identify segmentation types, industry trends, key players, competitive landscape, key market dynamics, and key player strategies.
Secondary Research
This research study involved the usage of comprehensive secondary sources, directories, databases such as Bloomberg Business, Factiva, and Dun & Bradstreet; white papers; annual reports; company house documents; investor presentations; and SEC filings of companies. Secondary research was used to identify and collect information useful for an extensive, technical, market-oriented, and commercial study of the leukapheresis market. It was also used to identify key players in the market and classify and segment the industry based on trends to the most detailed level. Additionally, significant developments related to market and technology perspectives were noted. A database of the primary industry leaders was also created using secondary research.
Primary Research
In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources from the supply side include project/sales/marketing/business development managers, presidents, CEOs, vice presidents, chairpersons, chief operating officers, chief strategy officers, directors, chief information officers, and chief medical information officers related to the leukapheresis market. Primary sources from the demand side include healthcare professionals from blood component providers & blood centers, academic & research institutes, pharmaceutical & biotechnology companies, and hospitals & transfusion centers.
A breakdown of the primary respondents is provided below:
BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE PARTICIPANTS, BY COMPANY TYPE, DESIGNATION, AND REGION

Note 1: C-level executives include CEOs, COOs, CTOs, and VPs.
Note 2: Other designations include sales, marketing, and product managers.
Note 3: Tiers are defined based on a company’s total revenue. As of 2024: Tier 1 = >USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3 = <USD 500 million
To know about the assumptions considered for the study, download the pdf brochure
The total size of the leukapheresis market was determined after data triangulation from three approaches, as mentioned below. After each approach, the weighted average of the three approaches was taken based on the level of assumptions used in each approach.

After arriving at the market size, the total market was divided into several segments and subsegments. Data triangulation and market breakdown procedures were employed wherever applicable to complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments.
Leukapheresis is the process of separating white blood cells from the whole blood. Therapeutic leukapheresis procedures are used to treat hyperleukocytic leukemia, including acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), multiple myeloma, and non-Hodgkin’s lymphoma.
Leukopaks are enriched leukapheresis products that contain mononuclear leukocytes (lymphocytes and monocytes) and are used to develop cell-based therapeutics
Key Stakeholders
Report Objectives
Detailed analysis and profiling of additional market players (up to 5)
Further breakdown of the Rest of Europe leukapheresis market into Austria, Finland, and other countries
Further breakdown of the Rest of Latin America leukapheresis market into Colombia, Chile, and other countries
Market share analysis for North America and Europe, which provides market shares of the top 3–5 key players in the leukapheresis market
Competitive leadership mapping for established players in the US
Full forecast, segment splits, and company analysis for all Leukapheresis Market.
Customize this report to your needs
Get 10% FREE Customization
Customize This Report